Short Interest in Blue Water Biotech, Inc. (NASDAQ:BWV) Declines By 22.6%

Blue Water Biotech, Inc. (NASDAQ:BWVGet Free Report) was the recipient of a large decline in short interest during the month of August. As of August 15th, there was short interest totalling 280,600 shares, a decline of 22.6% from the July 31st total of 362,600 shares. Based on an average daily volume of 1,030,000 shares, the short-interest ratio is currently 0.3 days. Approximately 2.4% of the company’s shares are short sold.

Blue Water Biotech Stock Performance

BWV stock traded down $0.00 during trading on Wednesday, hitting $0.85. The company had a trading volume of 59,582 shares, compared to its average volume of 1,065,609. Blue Water Biotech has a 12 month low of $0.73 and a 12 month high of $3.64.

Blue Water Biotech Company Profile

(Get Free Report)

Blue Water Biotech, Inc, a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia.

Featured Stories

Receive News & Ratings for Blue Water Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blue Water Biotech and related companies with's FREE daily email newsletter.